Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.
暂无分享,去创建一个
Danny Vesprini | Alexandre Mamedov | Liying Zhang | L. Klotz | Suneil Jain | D. Vesprini | A. Loblaw | Laurence Klotz | Suneil Jain | Liying Zhang | A. Mamedov | P. Sethukavalan | V. Jethava | Toshihiro Yamamoto | Andrew Loblaw | Perakaa Sethukavalan | Vibhuti Jethava | Toshihiro Yamamoto | S. Jain
[1] M. Terris,et al. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. , 2008, Urology.
[2] M. Remzi,et al. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. , 2005, The Journal of urology.
[3] Kirsten L. Greene,et al. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. , 2015, The Journal of urology.
[4] Liying Zhang,et al. Gleason Upgrading with Time in a Large Prostate Cancer Active Surveillance Cohort. , 2015, The Journal of urology.
[5] Liying Zhang,et al. Modeling prostate specific antigen kinetics in patients on active surveillance. , 2006, The Journal of urology.
[6] D. Lin. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: Characteristics, PSA doubling times, and outcome , 2007 .
[7] Steve Williams,et al. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience , 2007, BJU international.
[8] L. Klotz. Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. , 2004, The Journal of urology.
[9] Alan Horwich,et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. , 2008, European urology.
[10] K. Ali,et al. PSA doubling time predicts the outcome after active surveillance in screening‐detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section , 2006 .
[11] Neil Fleshner,et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. , 2002, The Journal of urology.
[12] Jennifer R. Rider,et al. Natural history of early, localized prostate cancer: a final report from three decades of follow-up. , 2013, European urology.
[13] B. Efron. Bootstrap Methods: Another Look at the Jackknife , 1979 .
[14] E. Metter,et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience , 2007 .
[15] Liying Zhang,et al. Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance. , 2010, The Journal of urology.
[16] W. J. Morris,et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] L. Klotz. Active surveillance for prostate cancer: for whom? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Alexandre Mamedov,et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Andrew J Vickers,et al. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] P. Carroll,et al. 20-year outcomes following conservative management of clinically localized prostate cancer , 2005 .
[21] D. G. Altman,et al. Review of survival analyses published in cancer journals. , 1995, British Journal of Cancer.